血清胸苷激酶1在骨肉瘤疗效评价中的临床应用

Application of serum thymidine Kinase 1 in the evaluation of the curative effect of juvenile osteosarcoma

目的通过检测骨肉瘤规范化治疗前后血清胸苷激酶1变化,评估患者治疗效果、复发或转移风险.方法选取2011年1月至2015年6月山东大学齐鲁医院(青岛)收治的骨肉瘤患者63例(骨肉瘤组)及30例健康体检者(对照组)为研究对象,采用免疫印迹增强化学发光法检测血清胸苷激酶1水平及阳性率.结果病程2周时,骨肉瘤组患者血清胸苷激酶1水平明显高于对照组,差异有统计学意义(P<0.05).骨肉瘤组化疗敏感与化疗不敏感患者术后3个月血清胸苷激酶1水平差异有统计学意义(P<0.05),无局部复发与局部复发患者术后3个月血清胸苷激酶1水平差异有统计学意义(P<0.05),无转移患者与早期出现转移的患者术后3个月血清胸苷激酶1水平差异有统计学意义(P<0.05).结论检测骨肉瘤患者血清胸苷激酶1,对手术前后化疗效果评估、肿瘤复发、转移风险预测有重要意义.

Objective To evaluate the clinical application of serum thymidine kinase 1(S-TK1)in the evaluation of the curative effect of juvenile osteosarcoma.Methods From January 2011 to June 2015,63 patients with osteosarcoma and 30 cases accepting health examination were collected as the control group.The level and positive rate of S-TK1 in each group were detected and compared.Results The S TK1 level of the osteosarcoma group with a course of 2 weeks was higher than that of the control group,and the difference was statistically significant(P<0.05).In the osteosarcoma patients,the difference of S-TK1 level in patients between chemotherapy sensitive group and insensitive group was statistically(P<0.05).The difference of STK1 level between patients without local recurrence and patients with local recurrence had statistical difference(P<0.05).The difference of S-TK1 level between patients without distant metastasis and patients with distant metastasis had statistical difference(P<0.05).Conclusion The detection of S TK1 in osteosarcoma patients has great significance for predicting the effect of chemotherapy and the risk of recurrence and metastasis.